For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Tango Therapeutics Inc (NASDAQ: TNGX) closed at $8.52 up 0.71% from its previous closing price of $8.46. In other words, the price has increased by $0.71 from its previous closing price. On the day, 11.06 million shares were traded. TNGX stock price reached its highest trading level at $8.85 during the session, while it also had its lowest trading level at $8.44.
Ratios:
For a deeper understanding of Tango Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.88 and its Current Ratio is at 8.88. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11. On July 17, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $19.Jefferies initiated its Buy rating on July 17, 2024, with a $19 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 23 ’25 when Third Rock Ventures IV, L.P. sold 477,401 shares for $10.15 per share. The transaction valued at 4,846,575 led to the insider holds 13,386,574 shares of the business.
Third Rock Ventures IV, L.P. bought 477,401 shares of TNGX for $3,594,830 on Oct 23 ’25. On Sep 25 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 500,000 shares for $8.02 each. As a result, the insider received 4,008,500 and left with 13,863,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 1147448832 and an Enterprise Value of 1028692864. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.25 while its Price-to-Book (P/B) ratio in mrq is 5.94. Its current Enterprise Value per Revenue stands at 15.469 whereas that against EBITDA is -9.533.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.78, which has changed by 1.6377709 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $11.20, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is -2.77%, while the 200-Day Moving Average is calculated to be 53.94%.
Shares Statistics:
For the past three months, TNGX has traded an average of 3.18M shares per day and 3037090 over the past ten days. A total of 111.57M shares are outstanding, with a floating share count of 88.66M. Insiders hold about 34.17% of the company’s shares, while institutions hold 72.56% stake in the company. Shares short for TNGX as of 1764288000 were 33248529 with a Short Ratio of 10.46, compared to 1761868800 on 29388713. Therefore, it implies a Short% of Shares Outstanding of 33248529 and a Short% of Float of 28.63.
Earnings Estimates
. The current rating of Tango Therapeutics Inc (TNGX) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.28 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.82 and -$1.0 for the fiscal current year, implying an average EPS of -$0.9. EPS for the following year is -$1.29, with 7.0 analysts recommending between -$1.13 and -$1.52.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $67.39M, while the lowest revenue estimate was $62.38M, resulting in an average revenue estimate of $62.95M. In the same quarter a year ago, actual revenue was $42.07M
